Johnson & Johnson: Strong Q3 Growth, But 2027 Could Test Its Earnings

Johnson & Johnson reported Q3 revenue of $25.4 billion, supported by Innovative Medicine's 7.9% operational growth, while MedTech lagged at 2.5%. Management raised its 2026 guidance and adjusted EPS. TREMFYA continues offsetting STELARA's decline, generating $2.4 billion in quarterly sales. Recent Ph.3 FUZION data further strengthen its clinical position. MedTech remains a concern, despite Shockwave's 17.2% growth. Weakeness in Surgery, Abiomed, and international markets highlights the need for broader operational improvement.

Seeking Alpha • 16 hours ago

Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher

Merck (NYSE:MRK | MRK Price Prediction) is the second big drugmaker to reward investors with an earnings beat and a raised profit outlook.

24/7 Wall Street • 9 hours ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ

NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson ("J&J" or the "Company") (NYSE: JNJ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

PRNewsWire • 10 hours ago

Johnson & Johnson (JNJ) Is Considered a Good Investment by Brokers: Is That True?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Zacks Investment Research • 9 hours ago

4 Dividend-Paying Dow Jones Industrial Stocks That Beat Q3 Estimates

Four blue-chip Dow dividend payers just topped Wall Street's third-quarter estimates, but their payout stories diverge sharply on yield, coverage, and growth. One just cut its quarterly check while another raised it 13.

24/7 Wall Street • 12 hours ago

VYM's Price May Be Soaring, but Its Dividend Isn't Keeping Up

VYM has handed shareholders a remarkable run, but the gap between share price growth and dividend growth is raising an uncomfortable question for retirees counting on that quarterly check.

24/7 Wall Street • 10 hours ago

Best Dividend Aristocrats For November 2026

Dividend Aristocrats underperformed SPY in September but rebounded sharply in October, narrowing the YTD gap. NOBL and the average Aristocrat have YTD returns of 13.13% and 13.35%, trailing SPY's 14.15%. Dividend growth among Aristocrats accelerated, with the 2026 average increase now at 4.55%, bolstered by recent double-digit hikes.

Seeking Alpha • 17 hours ago

3 Unstoppable S&P 500 Stocks to Buy Before October Ends

Coca-Cola is excelling during a difficult time for consumer staples companies. Johnson & Johnson provides investors with a diversified business in the healthcare sector.

The Motley Fool • 13 hours ago

The Big 3: AAPL, JNJ, MMM

As a tech selloff sparked by Alphabet (GOOGL) earnings grips the stock market, Dan Deming continues to see the rotation as the biggest unsung headline for equities. As for today's Big 3, he expects Apple (AAPL) to maintain tech dominance in earnings, sees Johnson & Johnson (JNJ) as a leader in the healthcare sector, and names 3M (MMM) as a strong defensive stock.

Johnson & Johnson to Host Enterprise Business Review

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will hold an Enterprise Business Review for the investment community on Tuesday, December 8th, 2026. During the event, Company leaders will provide a detailed review of the Innovative Medicine and MedTech businesses, highlight how their pipelines are shaping the future of healthcare, and discuss the Company's long-term strategy for delivering the next wave of growth and shareholder value. The Enterprise Business Review will.

Business Wire • Oct 27, 2026